Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 11, 2008, Pages 1334-1345

  Reenaers, Catherine ^a   Franchimont, Nathalie ^a   Oury, Cecile ^a   Belaiche, Jacques ^a   Malaise, Michel ^a   Bours, Vincent ^a   Theatre, Emilie ^a   Delvenne, Philippe ^a   Louis, Edouard ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Apoptosis; Crohn's disease; Human intestinal fibroblasts; TNF related apoptosis inducing ligand

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; INTERLEUKIN 6; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ADULT; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; APOPTOSIS; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; FIBROBLASTS; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 54349103802     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802200010     Document Type: Article

References (54)

1. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, et al. Increased production of tumor necrosis factor-alfa, interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-9.
2. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, Mac Dermott RP, et al. Enhanced secretion of tumour necrosis factor-alfa, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
3. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
4. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000;279:G653-9.
5. Hogaboam CM, Snider DP, Collins SM. Activation of T lymphocytes by syngeneic murine intestinal smooth muscle cells. Gastroenterology 1996;110:1456-66.
6. Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myofibroblasts as antigen presenting cells. J Immunol 1992;149:661-7.
7. Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, et al. Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. Gut 2004;53:85-90.
8. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997;151:317-22.
9. Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S. Connective tissue growth factors: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol 1998;30:909-22.
10. Nedelec B, Ghahary A, Scott PG, Tredget EE. Control of wound contraction. Basic and clinical features. Hand Clin 2000;16:289-302.
11. Gelbmann CM, Mestermann S, Gross V, Köllinger M, Schölmerich J, Falk W. Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 1999;45:210-7.
12. Kelly JK, Preshaw RM. Origin of fistulas in Crohn's disease. J Clin Gastroenterol 1989;11:193-6.
13. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
14. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
15. Jo M, Kim TH, Soel DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
16. Huang Y, Erdmann N, Peng H, Davis JS, Luo X, Ikezu T, et al. TRAIL-mediated apoptosis in HIV-1 infected macrophages is dependent on the inhibition of Akt-1 phosphorylation. J Immunol 2006;177:2304-13.
17. Kamohara H, Matsuyama W, Shimozato O, Abe K, Galligan C, Hashimoto S, et al. Regulation of TRAIL and TRAIL receptor expression in human neutrophils. Immunology 2004;111:186-94.
18. Rimondi E, Secchiero P, Quaroni A, Zerbinati C, Capitani S, Zauli G. Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. J Cell Physiol 2006;206:647-54.
19. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
20. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
21. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997;7:693-6.
22. Wu G, Burns TF, McDonald ER III, Meng RD, Kao G, Muschel R, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
23. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97.
24. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signalling and decoy receptors. Science 1997;277:818-21.
25. Kischkel FC, Hellbardt S, Behrman I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death- inducing signalling complex (DISC) with the receptor. EMBO J 1995;14:5579-88.
26. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599-609.
27. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272:25417-20.
28. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
29. Cremer I, Dieu-Nosjean MC, Maréchal S, Dezutter-Dambuyant C, Goddard S, Adams D, et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood 2002;100:3646-55.
30. Josien R, Wong BR, Li HL, Steinman RF, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162:2562-8.
31. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
32. Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004;138:491-8.
33. Begue B, Wajant H, Bambou JC, Dubuquoy L, Siegmund D, Beaulieu JF, et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006;130:1962-74.
34. Heid CA, Stevens J, Livak KJ, Williams PM. Real-time quantitative PCR. Genome Res 1996;6:986-94.
35. Ruemmele FM, Russo P, Beaulieu J, Dionne S, Levy E, Lentze MJ, et al. Susceptibility to FAS-induced apoptosis in human nontumoral enterocyte: role of co-stimulatory factors. J Cell Physiol 1999;181:45-54.
36. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-61.
37. Olivier S, Fillet M, Malaise M, Piette J, Bours V, Merville MP, et al. Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene. Biochem Pharmacol 2005;69:891-901.
38. Relic B, Benoit V, Franchimont N, Ribbens C, Kaiser MJ, Gillet P, et al. 15-deoxy-delta12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem 2004;279:22399-403.
39. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999;277:C1-9.
40. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999;277:C183-201.
41. Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, Göke M, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology 2003;125:1341-54.
42. Strater J, Walczak H, Pukrop T, von Müller L, Hasel C, Kornmann M, et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infection: Gastroenterology 2002;122:659-66.
43. Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003;200:327-35.
44. Miranda-Carus ME, Balsa A, Benito-Miguel M, De Ayala CP, Martin-Mola E. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 2004;50:2786-93.
45. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, et al. TRAIL R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003;171:1061-9.
46. Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns MP, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005;54:1590-6.
47. Yurovsky VV. Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts. Am J Respir Cell Mol Biol 2003;28:225-31.
48. Shiiki K, Yoshikawa H, Kinoshita H, Takeda M, Ueno A, Nakajima Y, et al. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Diff 2000;7:939-46.
49. Matysiak M, Jurewicz A, Jaskolski D, Selmaj K. TRAIL induces death of oligodendrocytes isolated from adult brain. Brain 2000;125:2469-80.
50. Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann NY Acad Sci 2002;973:166-80.
51. Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone 2005;37:601-6.
52. Miyashita T, Kawakami A, Nakashima T, Yamasaki S, Tamai M, Kamachi M, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblasts-like synovial cells. Clin Exp Immunol 2004;137:430-6.
53. Holen I, Croucher P, Hamdy F, Eaton C. Osteoprotegerin is a survival factor for human prostate cancer cells. Cancer Res 2002;1619-23.
54. Shipman C, Croucher P. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-6.